阿仑单抗与那他珠单抗、芬戈莫德和干扰素β治疗复发缓解型多发性硬化的疗效比较:队列研究
这项国际队列研究通过倾向性匹配比较阿仑单抗与那他珠单抗、芬戈莫德和干扰素β治疗复发缓解型多发性硬化的疗效。阿仑单抗年化复发率低于干扰素β和芬戈莫德,与那他珠单抗相似;残疾改善概率低于那他珠单抗。结论认为阿仑单抗和那他珠单抗高效,治疗选择应主要基于安全性。
要点
- 阿仑单抗年化复发率低于干扰素β和芬戈莫德,与那他珠单抗相似。
- 阿仑单抗残疾累积风险与三种对照药均相似。
- 阿仑单抗残疾改善概率低于那他珠单抗。
核心结论
- 阿仑单抗与那他珠单抗对年化复发率效果相似。
- 阿仑单抗在减少复发活动方面似乎优于芬戈莫德和干扰素β。
- 那他珠单抗在促进残疾恢复方面似乎优于阿仑单抗。
研究设计与样本
- 国际队列研究,使用MSBase和六个其他队列的倾向性匹配患者数据。
- 阿仑单抗189例,干扰素β 2155例,芬戈莫德828例,那他珠单抗1160例。
临床怎么用
- 阿仑单抗和那他珠单抗均为高效免疫治疗选择。
- 两者之间的选择应主要基于安全性特征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Alemtuzumab, an anti-CD52 antibody, is proven to be more efficacious than interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis, but its efficacy relative to more potent immunotherapies is unknown. We compared the effectiveness of alemtuzumab with natalizumab, fingolimod, and interferon beta in patients with relapsing-remitting multiple sclerosis treated for up to 5 years. METHODS: In this international cohort study, we used data from propensity-matched patients with relapsing-remitting multiple sclerosis from the MSBase and six other cohorts. Longitudinal clinical data were obtained from 71 MSBase centres in 21 countries and from six non-MSBase centres in the UK and Germany between Nov 1, 2015, and June 30, 2016. Key inclusion criteria were a diagnosis of definite relapsing-remitting multiple sclerosis, exposure to one of the study therapies (alemtuzumab, interferon beta, fingolimod, or natalizumab), age 65 years or younger, Expanded Disability Status Scale (EDSS) score 6·5 or lower, and no more than 10 years since the first multiple sclerosis symptom. The primary endpoint was annualised relapse rate. The secondary endpoints were cumulative hazards of relapses, disability accumulation, and disability improvement events. We compared relapse rates with negative binomial models, and estimated cumulative hazards with conditional proportional hazards models. FINDINGS: Patients were treated between Aug 1, 1994, and June 30, 2016. The cohorts consisted of 189 patients given alemtuzumab, 2155 patients given interferon beta, 828 patients given fingolimod, and 1160 patients given natalizumab. Alemtuzumab was associated with a lower annualised relapse rate than interferon beta (0·19 [95% CI 0·14-0·23] vs 0·53 [0·46-0·61], p<0·0001) and fingolimod (0·15 [0·10-0·20] vs 0·34 [0·26-0·41], p<0·0001), and was associated with a similar annualised relapse rate as natalizumab (0·20 [0·14-0·26] vs 0·19 [0·15-0·23], p=0·78). For the disability outcomes, alemtuzumab was associated with similar probabilities of disability accumulation as interferon beta (hazard ratio [HR] 0·66 [95% CI 0·36-1·22], p=0·37), fingolimod (1·27 [0·60-2·70], p=0·67), and natalizumab (0·81 [0·47-1·39], p=0·60). Alemtuzumab was associated with similar probabilities of disability improvement as interferon beta (0·98 [0·65-1·49], p=0·93) and fingolimod (0·50 [0·25-1·01], p=0·18), and a lower probability of disability improvement than natalizumab (0·35 [0·20-0·59], p=0·0006). INTERPRETATION: Alemtuzumab and natalizumab seem to have similar effects on annualised relapse rates in relapsing-remitting multiple sclerosis. Alemtuzumab seems superior to fingolimod and interferon beta in mitigating relapse activity. Natalizumab seems superior to alemtuzumab in enabling recovery from disability. Both natalizumab and alemtuzumab seem highly effective and viable immunotherapies for multiple sclerosis. Treatment decisions between alemtuzumab and natalizumab should be primarily governed by their safety profiles. FUNDING: National Health and Medical Research Council, and the University of Melbourne.
引用
- Kalincik T, Brown JWL, Robertson N, et al. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Lancet Neurol. 2017. PMID: 28209331. doi:10.1016/S1474-4422(17)30007-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。